Treatment with cannabidiol led to improved seizure and nonseizure outcomes in patients with various forms of epilepsy, data show. The BECOME-TSC study evaluated outcomes of Epidiolex (Jazz ...

ScienceAlert reports how a team of researchers in Brazil found that the fruits and flowers of Trema micrantha blume — a type ...

DelveInsight's“Lennox–Gastaut syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lennox–Gastaut syndrome, historical and forecasted ...

Bexicaserin is being developed to treat a group of disorders known as developmental and epileptic encephalopathies (DEEs), including Dravet syndrome ... reduced seizure frequency by more than ...

Epidyolex is the first cannabis-based medicine for epilepsy to be licensed and recommended for use in the NHS. This is very welcome and offers a much needed additional treatment option for people ...

The St. Louis Business Journal's Innovation in Philanthropy Awards program, now in its sixth year, celebrates local ...

Research has also explored the effectiveness of VNS in children with genetic forms of epilepsy, such as Dravet syndrome and tuberous sclerosis complex. The results showed that while VNS did not ...

Joel Stanley, the founder and former CEO of Charlotte’s Web, is leading an effort to achieve approval from the FDA for a novel treatment to treat autism spectrum ...

Substantial and durable reductions in convulsive seizure frequency were observed ... for zorevunersen for the treatment of Dravet syndrome with a confirmed mutation, not associated with gain ...

Jan. 22, 2025 — Doctors could soon reduce epilepsy misdiagnoses by up to 70% using a new tool that turns routine electroencephalogram, or EEG, tests that appear normal into highly accurate ...

Advancements in precision medicine drive the 5-HT2 agonist market by enabling selective targeting of specific receptor subtypes (e.g., 5-HT2A or 5-HT2C), reducing side effects and improving safety.